Summary (tl;dr)

A U.S. federal advisory panel has voted to remove the recommendation for universal hepatitis B vaccination of all newborns, shifting towards individualized decision-making for infants whose mothers test negative for the virus. This controversial decision marks a significant change to a decades-old public health strategy and has drawn strong criticism from medical experts.

Essential Background

For over three decades, since 1991, the Centers for Disease Control and Prevention (CDC) has recommended that all newborns in the United States receive a hepatitis B vaccine within 24 hours of birth. This universal vaccination strategy has been widely credited with dramatically reducing hepatitis B infections in children and young adults, with studies showing a 99% decline in acute cases between 1990 and 2019. Hepatitis B is a serious viral infection that can lead to chronic liver disease, cancer, and death, and infants infected at birth have a high chance of developing chronic infection. The vaccine is considered safe and highly effective.

The Full Story

On Friday, December 5, 2025, the Advisory Committee on Immunization Practices (ACIP), a key advisory panel to the CDC, voted 8-3 to revise the U.S. childhood immunization schedule for the hepatitis B vaccine. The panel recommended ending the universal birth dose for infants born to mothers who test negative for hepatitis B. Instead, for these infants, ACIP now suggests "individual-based decision-making" in consultation with a healthcare provider, with the initial dose to be administered no earlier than two months of age if parents choose to vaccinate. This shift has been met with immediate condemnation from various medical and public health organizations, including the American Academy of Pediatrics, who argue it is an "irresponsible and purposely misleading" guidance that could lead to an increase in infections. The panel's current members were appointed by U.S. Health Secretary Robert F. Kennedy Jr., who is noted for his skeptical views on vaccines, and this decision is considered the most significant change to the childhood immunization schedule under his leadership.

Why It Matters

This change to the hepatitis B vaccination recommendation is significant because it departs from a successful public health strategy that has nearly eradicated the virus among U.S. children. Critics warn that delaying or making the birth dose optional for some infants could lead to a resurgence of hepatitis B infections, as many infected mothers may not know their status, and infants are highly vulnerable to chronic infection if exposed. Medical experts emphasize that the vaccine's safety and effectiveness for newborns have been well-established over decades. The decision also raises concerns about potential impacts on vaccine confidence and the possibility that public insurance programs may no longer be required to cover the birth dose, potentially creating access barriers for millions of families.

Geographic Location

• CDC Headquarters, Atlanta, Fulton County, Georgia, United States (location of ACIP meeting and vote)